We are live on
!
Find out more
RC
Rangeley Capital Portfolio holdings
AUM
$109M
1-Year Est. Return
97.13%
This Fund
S&P 500
This Quarter
Est. Return
+28.51%
1 Year Est. Return
+97.13%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$31.8M
(+38%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
11.97%
Top 10 Holdings %
Top 10 Hldgs %
43.17%
Holding
151
New
78
Increased
26
Reduced
12
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Yext
YEXT
|
+$4.63M |
| 2 |
TACO
Berto Acquisition Corp
TACO
|
+$3.29M |
| 3 |
Cogent Communications
CCOI
|
+$1.24M |
| 4 |
Liquidia Corp
LQDA
|
+$1.11M |
| 5 |
ECHO
EchoStar
ECHO
|
+$1.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$6.66M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$3.01M |
| 3 |
Delek US
DK
|
+$2.79M |
| 4 |
SKX
Skechers
SKX
|
+$2.27M |
| 5 |
THRD
Third Harmonic Bio
THRD
|
+$1.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.16% |
| 2 | Miscellaneous | 11.84% |
| 3 | Financials | 11.03% |
| 4 | Energy | 9.32% |
| 5 | Communication Services | 8.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
International Money Express
IMXI
$427M
| $140K | 0.12% |
+10,000
| New | +$124K |
|
|
BXBL
102
BOXABL Inc
BXBL
$1.41B
| $135K | 0.12% |
+13,531
| New | +$135K |
|
103
Dole
DOLE
$1.28B
| $134K | 0.12% |
+10,000
| New | +$140K |
|
|
AIFC
104
AI Financial Corp
AIFC
$72.4M
| $130K | 0.11% |
+48,300
| New | +$289K |
|
|
HCMA
105
HCM III Acquisition Corp
HCMA
$348M
| $127K | 0.11% |
+12,530
| New | +$127K |
|
106
SITE Centers
SITC
$147M
| $126K | 0.11% |
14,000
-26,001
| -65% | -$276K |
|
|
IMA
107
ImageneBio Inc
IMA
$58.3M
| $122K | 0.11% |
+15,000
| New | +$199K |
|
|
AIV
108
Aimco
AIV
$351M
| $119K | 0.1% |
+15,000
| New | +$122K |
|
|
MCGAU
109
Yorkville Acquisition Corp Unit
MCGAU
| $111K | 0.1% |
+10,000
| New | +$111K |
|
110
MoonLake Immunotherapeutics
MLTX
$1.08B
| $108K | 0.09% |
+15,000
| New | +$782K |
|
|
TACOW
111
Berto Acquisition Corp Warrant
TACOW
$16.2M
| $104K | 0.09% |
+10,000
| New | +$6.96K |
|
112
Pliant Therapeutics
PLRX
$72.4M
| $89.1K | 0.08% |
60,220
| – | – |
|
113
AN2 Therapeutics
ANTX
$215M
| $82.5K | 0.07% |
65,000
| – | – |
|
114
Bit Digital
BTBT
$591M
| $68.8K | 0.06% |
+22,950
| New | +$69.6K |
|
115
PMV Pharmaceuticals
PMVP
$79.7M
| $63.7K | 0.06% |
+45,500
| New | +$62.9K |
|
116
Adicet Bio
ACET
$90.7M
| $60.8K | 0.05% |
+4,688
| New | +$55.2K |
|
117
Spero Therapeutics
SPRO
$67M
| $56.4K | 0.05% |
+30,000
| New | +$66K |
|
118
Amplify Energy
AMPY
$205M
| $52.5K | 0.05% |
10,000
-270,000
| -96% | -$1.06M |
|
119
MacroGenics
MGNX
$252M
| $50.8K | 0.04% |
30,220
+3,220
| +12% | +$5.21K |
|
|
ANEB
120
DELISTED
Anebulo Pharmaceuticals
ANEB
| $50K | 0.04% |
+20,000
| New | +$47.1K |
|
121
Replimune Group
REPL
$1.2B
| $43.6K | 0.04% |
+10,400
| New | +$66.5K |
|
122
Seer Inc
SEER
$108M
| $43.4K | 0.04% |
20,000
+10,000
| +100% | +$21.3K |
|
123
Rallybio
RLYB
$88.7M
| $41.4K | 0.04% |
+10,376
| New | +$43.6K |
|
124
Cabaletta Bio
CABA
$487M
| $26.4K | 0.02% |
11,300
-4,700
| -29% | -$8.06K |
|
|
FRMM
125
Forum Markets
FRMM
$60.1M
| $24.1K | 0.02% |
+1,000
| New | +$29.9K |
|
Similar funds
GCM
SSCM
RCM
BWM
QFMHK
AC
ANBOT
SCA
Rangeley Capital's Q3 2025 Portfolio in Review
As of Q3 2025, Rangeley Capital held 151 positions worth $116M, up 38% from $83.8M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Rangeley Capital deployed $13.8M of net new capital in Q3 2025, opening 78 new positions and adding to 26 existing holdings. Its largest new stake was Yext: 545,000 shares worth $4.64M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 47% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Delek US, an estimated $2.79M trimmed.
- Rangeley Capital's largest Q3 2025 buy was Yext: 545,000 shares worth $4.64M.
- Rangeley Capital added most to GSR III Acquisition Corp in Q3 2025, an estimated $941K increase.
- Rangeley Capital's biggest Q3 2025 reduction was Delek US, cutting an estimated $2.79M.
- Rangeley Capital fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.66M.
- Rangeley Capital's ten largest holdings make up 43% of its $116M portfolio in Q3 2025.
- Rangeley Capital opened 78 new positions and closed 24 in Q3 2025.
- Rangeley Capital's portfolio value rose 38% quarter-over-quarter to $116M.
Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.